N(1)-methyl-2-pyridone-5-carboxylic acid

07/01/2023 - "In non-metastatic prostate cancer (nmPCa) setting, it is important to early identify the patients at risk of biochemical recurrence (BCR) for immediate postoperative intervention. "
07/01/2017 - "Age and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. "
01/01/2022 - "Ten studies and 7,986 patients were enrolled in our meta-analysis, 1,442 patients were diagnosed with metastatic-castration resistant prostate cancer (mCRPC), and 6544 patients were diagnosed with non-metastatic prostate cancer (nmPCa). "
01/01/2021 - "The aim of this study was to investigate the clinical significance of the effect of age on disease control in men who received high-dose intensity-modulated radiation therapy (IMRT) for nonmetastatic prostate cancer (NMPCa). "
01/01/2022 - "Simple Summary: Although radiotherapy plays a fundamental role in the management of intermediate/high/very high-risk non-metastatic prostatic cancer (IHR-nmPca), there is still no consensus on the optimal treatment strategy in this setting. "

11/01/2023 - "Patients with nonmetastatic prostate cancer (nmPCa) and high prostate-specific antigen (PSA) levels due to the high likelihood of metastasis pose a clinical dilemma regarding their optimal treatment and long-term outcomes after initial local therapy. "
01/01/2021 - "We assessed clinical and tumor biological features and evaluated their association with positive surgical margins (PSMs) and positive apical margins (PAMs) variability after radical prostatectomy (RP) in men with non-metastasis prostate cancer (nmPCa) in our institute. "
01/01/2022 - "To evaluate metastasis-free survival (MFS) and toxicity after SBRT to dual-tracer PET/CT-detected metastases in patients with nmPCa and early prostate-specific antigen (PSA) progression on androgen deprivation therapy (ADT; PSA ≤2 ng/ml). "

01/01/2021 - "NMPCa patients with favorable intermediate to very high-risk features (National Comprehensive Cancer Network risk classification) treated with IMRT at our institution between September 2000 and May 2011 were analyzed retrospectively. "
01/01/2021 - "We assessed clinical and tumor biological features and evaluated their association with positive surgical margins (PSMs) and positive apical margins (PAMs) variability after radical prostatectomy (RP) in men with non-metastasis prostate cancer (nmPCa) in our institute. "

01/01/1985 - "Non-metric principal components analysis (NMPCA) showed that the structure was three-dimensional, the dimensions being labelled: Shortness of breath (HVS-1), Peripheral tetany (HVS-II), Central tetany (HVS-III). "

01/01/1985 - "Non-metric principal components analysis (NMPCA) showed that the structure was three-dimensional, the dimensions being labelled: Shortness of breath (HVS-1), Peripheral tetany (HVS-II), Central tetany (HVS-III). "